10X Genomics Inc
$ 18.89
0.05%
23 Feb - close price
- Market Cap 2,413,240,000 USD
- Current Price $ 18.89
- High / Low $ 18.92 / 18.32
- Stock P/E N/A
- Book Value 6.24
- EPS -0.35
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.06 %
- 52 Week High 23.56
- 52 Week Low 6.78
About
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
Analyst Target Price
$19.79
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-10-28 | 2025-08-07 | 2025-05-08 | 2025-02-12 | 2024-10-29 | 2024-08-08 | 2024-04-30 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-03 |
| Reported EPS | 0.0705 | -0.0228 | 0.28 | -0.28 | -0.14 | -0.02 | -0.32 | -0.5 | -0.41 | -0.79 | -0.53 | -0.44 |
| Estimated EPS | -0.2167 | -0.07 | -0.31 | -0.47 | -0.11 | -0.26 | -0.48 | -0.5 | -0.36 | -0.46 | -0.4 | -0.37 |
| Surprise | 0.2872 | 0.0472 | 0.59 | 0.19 | -0.03 | 0.24 | 0.16 | 0 | -0.05 | -0.33 | -0.13 | -0.07 |
| Surprise Percentage | 132.5335% | 67.4286% | 190.3226% | 40.4255% | -27.2727% | 92.3077% | 33.3333% | 0% | -13.8889% | -71.7391% | -32.5% | -18.9189% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.284 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TXG
2026-02-21 18:38:10
The Hardman & Co Healthcare Index (HHI) fell 3.7% in 2023, underperforming major London markets due to the capital-intensive nature of the life sciences sector. Despite challenges in raising capital, 15 companies in the index secured new funding, and 2024 is projected to be busy as more companies will require capital to satisfy auditors. The index, running since 2009, aims to highlight the long-term attractiveness of life sciences investments.
2026-02-12 21:11:04
10x Genomics reported significantly narrowed losses in 2025, driven by improved profitability and reduced operating expenses, despite only modest revenue growth. The company also provided cautious revenue guidance for 2026, projecting 0% to 4% growth when excluding one-time patent litigation settlement revenue from 2025. This financial update highlights a strategic shift towards profitability amidst a challenging market, supported by strong cash reserves and strategic partnerships.
2026-02-11 21:28:11
10x Genomics is set to release its Q4 2025 earnings report this Thursday, with analysts forecasting a revenue of $159.2 million and an adjusted loss per share of $0.04. The company previously beat revenue and EPS estimates in the last quarter, though its stock has recently declined by 4.5%. The broader life sciences tools and services sector has also underperformed, while discussions about tariffs and corporate tax changes add to economic uncertainty.
2026-02-07 06:45:28
10x Genomics has partnered with PharosAI, a UK consortium, in an £18.9 million initiative to convert thousands of archived NHS cancer samples into one of the world's largest multimodal datasets. This project aims to create AI-ready genomic, transcriptomic, imaging, and spatial biology data to accelerate cancer diagnosis, precision therapies, and drug discovery. The program, backed by the UK Research Ventures Catalyst and running through 2027, will democratize secure access to these datasets for researchers globally.
2026-02-04 15:00:00
PharosAI, a research consortium backed by £18.9 million from the UK Government, is partnering with 10x Genomics to create one of the world's most comprehensive multimodal cancer datasets. They will use 10x Genomics' Xenium spatial platform to analyze archived NHS cancer samples and build advanced AI models for earlier diagnosis, precision therapies, and new treatment discovery, initially focusing on breast cancer. The initiative aims to democratize access to these AI-ready datasets for researchers and innovators globally.
2026-02-04 09:00:00
PharosAI, a research consortium backed by £18.9 million from the UK Government and other partners, is partnering with 10x Genomics to create one of the world's most comprehensive multimodal cancer datasets using AI and spatial biology. The initiative will leverage 10x Genomics' Xenium spatial platform to transform archived NHS cancer samples into high-resolution datasets, which will be paired with advanced AI models to accelerate earlier diagnosis, enable precision therapies, and speed the discovery of new treatments, starting with breast cancer. This collaboration aims to democratize access to these datasets, positioning the UK at the forefront of AI-driven cancer research.
